Osteonecrosis

1
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Vericel
VericelCAMBRIDGE, MA
1 program
1
Ixmyelocel-TPhase 31 trial
Active Trials
NCT00505219Completed11Est. Dec 2010
Medacta
MedactaSwitzerland - Castel San Pietro
1 program
MOTO MedialN/A1 trial
Active Trials
NCT04072055TerminatedEst. Mar 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
VericelIxmyelocel-T
MedactaMOTO Medial

Clinical Trials (2)

Total enrollment: 11 patients across 2 trials

NCT00505219VericelIxmyelocel-T

Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head

Start: Sep 2007Est. completion: Dec 201011 patients
Phase 3Completed

MOTO Post-marketing Surveillance Study

Start: Sep 2019Est. completion: Mar 2023
N/ATerminated

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space